Quiflapon (BioDeep_00000668720)

   


代谢物信息卡片


Quiflapon

化学式: C34H35ClN2O3S (586.205679)
中文名称: 喹夫拉朋
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)O
InChI: InChI=1S/C34H35ClN2O3S/c1-33(2,3)41-31-27-18-26(40-21-25-15-12-23-8-6-7-9-28(23)36-25)16-17-29(27)37(20-22-10-13-24(35)14-11-22)30(31)19-34(4,5)32(38)39/h6-18H,19-21H2,1-5H3,(H,38,39)

描述信息

D004791 - Enzyme Inhibitors > D058946 - 5-Lipoxygenase-Activating Protein Inhibitors
C471 - Enzyme Inhibitor > C1322 - Lipooxygenase Inhibitor

同义名列表

2 个代谢物同义名

Quiflapon; MK-0591



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Zehra Tuğçe Gür, Burcu Çalışkan, Erden Banoglu. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis. European journal of medicinal chemistry. 2018 Jun; 153(?):34-48. doi: 10.1016/j.ejmech.2017.07.019. [PMID: 28784429]
  • Wen-Feng Fang, Ivor S Douglas, Chin-Chou Wang, Hsu-Ching Kao, Ya-Ting Chang, Chia-Cheng Tseng, Kuo-Tung Huang, Huang-Chih Chang, Meng-Chih Lin. 5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation. PloS one. 2014; 9(7):e102622. doi: 10.1371/journal.pone.0102622. [PMID: 25025775]
  • Chanaka Mendis, Katherine Campbell, Rina Das, David Yang, Marti Jett. Effect of 5-lipoxygenase inhibitor MK591 on early molecular and signaling events induced by staphylococcal enterotoxin B in human peripheral blood mononuclear cells. The FEBS journal. 2008 Jun; 275(12):3088-98. doi: 10.1111/j.1742-4658.2008.06462.x. [PMID: 18479466]
  • Dwight Macdonald, Christine Brideau, Chi Chung Chan, Jean-Pierre Falgueyret, Richard Frenette, Jocelyne Guay, John H Hutchinson, Hélène Perrier, Peptiboon Prasit, Denis Riendeau, Philip Tagari, Michel Thérien, Robert N Young, Yves Girard. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein. Bioorganic & medicinal chemistry letters. 2008 Mar; 18(6):2023-7. doi: 10.1016/j.bmcl.2008.01.105. [PMID: 18276139]
  • Richard Yang Cao, Michael A Adams, Andreas J Habenicht, Colin D Funk. Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostaglandins & other lipid mediators. 2007 Aug; 84(1-2):34-42. doi: 10.1016/j.prostaglandins.2007.03.005. [PMID: 17643886]
  • A Guasch, C F Zayas, K F Badr. MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis. Kidney international. 1999 Jul; 56(1):261-7. doi: 10.1046/j.1523-1755.1999.00537.x. [PMID: 10411701]
  • M Depré, A Van Hecken, R Verbesselt, I De Lepeleire, J Schwartz, A Porras, P Larson, C Lin, P J De Schepper. Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man. International journal of clinical pharmacology research. 1998; 18(2):53-61. doi: . [PMID: 9675622]
  • C Lin, J Y Hsieh, B K Matuszewski, M R Dobrinska. An automated sample preparation and high performance liquid chromatographic method for the determination of MK-591, a novel leukotriene biosynthesis inhibitor, in human plasma. Journal of pharmaceutical and biomedical analysis. 1996 Aug; 14(11):1601-8. doi: 10.1016/0731-7085(96)01737-2. [PMID: 8877868]
  • T Uematsu, M Kanamaru, K Kosuge, K Hara, N Uchiyama, N Takenaga, W Tanaka, B S Friedman, M Nakashima. Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers. British journal of clinical pharmacology. 1995 Jul; 40(1):59-66. doi: 10.1111/j.1365-2125.1995.tb04535.x. [PMID: 8527269]
  • R Petric, A Ford-Hutchinson. Inhibition of leukotriene biosynthesis improves renal function in experimental glomerulonephritis. Journal of lipid mediators and cell signalling. 1995 May; 11(3):231-40. doi: 10.1016/0929-7855(94)00040-j. [PMID: 7551679]
  • A B Becker, C Black, M K Lilley, K Bajwa, A W Ford-Hutchinson, F E Simons, P Tagari. Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs. Journal of applied physiology (Bethesda, Md. : 1985). 1995 Feb; 78(2):615-22. doi: 10.1152/jappl.1995.78.2.615. [PMID: 7759431]
  • R Petric, D W Nicholson, A W Ford-Hutchinson. Renal leukotriene C4 synthase: characterization, partial purification and alterations in experimental glomerulonephritis. Biochimica et biophysica acta. 1995 Jan; 1254(2):207-15. doi: 10.1016/0005-2760(94)00185-2. [PMID: 7827126]
  • Z Diamant, M C Timmers, H van der Veen, B S Friedman, M De Smet, M Depré, D Hilliard, E H Bel, P J Sterk. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. The Journal of allergy and clinical immunology. 1995 Jan; 95(1 Pt 1):42-51. doi: 10.1016/s0091-6749(95)70151-6. [PMID: 7822663]
  • M Depré, B Friedman, A Van Hecken, I de Lepeleire, W Tanaka, A Dallob, S Shingo, A Porras, C Lin, P J de Schepper. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor. Clinical pharmacology and therapeutics. 1994 Jul; 56(1):22-30. doi: 10.1038/clpt.1994.96. [PMID: 8033491]
  • M E Surette, A Odeimat, R Palmantier, S Marleau, P E Poubelle, P Borgeat. Reverse-phase high-performance liquid chromatography analysis of arachidonic acid metabolites in plasma after stimulation of whole blood ex vivo. Analytical biochemistry. 1994 Feb; 216(2):392-400. doi: 10.1006/abio.1994.1057. [PMID: 8179194]
  • P Tagari, C Brideau, C Chan, R Frenette, C Black, A Ford-Hutchinson. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. Agents and actions. 1993 Sep; 40(1-2):62-71. doi: 10.1007/bf01976753. [PMID: 8147271]
  • P Tagari, A Becker, C Brideau, R Frenette, V Sadl, E Thomas, P Vickers, A Ford-Hutchinson. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591. The Journal of pharmacology and experimental therapeutics. 1993 Apr; 265(1):416-25. doi: NULL. [PMID: 8386242]
  • P Prasit, M Belley, M Blouin, C Brideau, C Chan, S Charleson, J F Evans, R Frenette, J Y Gauthier, J Guay. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. Journal of lipid mediators. 1993 Mar; 6(1-3):239-44. doi: ". [PMID: 8357985]